Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/20/2017 04/21/2017 04/24/2017 04/25/2017 04/26/2017 Date
15.95(c) 15.85(c) 16(c) 16.5(c) 16.5(c) Last
638 105 782 788 1 366 201 766 218 1 001 714 Volume
-0.31% -0.63% +0.95% +3.13% 0.00% Change
More quotes
Financials ($)
Sales 2017 568 M
EBIT 2017 43,1 M
Net income 2017 25,2 M
Debt 2017 63,9 M
Yield 2017 -
Sales 2018 529 M
EBIT 2018 30,4 M
Net income 2018 -22,2 M
Finance 2018 51,5 M
Yield 2018 -
P/E ratio 2017 58,93
P/E ratio 2018
EV / Sales2017 1,47x
EV / Sales2018 1,36x
Capitalization 772 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
04/20 ACORDA NOTIFICATION : Faruqi & Faruqi, LLP Encourages Investors Who Suffered Los..
04/13 ACORDA THERAPEUTICS : U.S. District Court Issues Decision to Invalidate Four AMP..
04/13 ACORDA THERAPEUTICS : Implements Corporate Restructuring to Align Cost Structure..
04/13 ACORDA THERAPEUTICS : to Host Conference Call to Discuss First Quarter 2017 on A..
04/06 ACORDA THERAPEUTICS, INC. (NASDAQ : ACOR) Files An 8-K Costs Associated with Exi..
04/06 ACORDA THERAPEUTICS INC : Costs Associated with Exit or Disposal Activities, Fin..
04/06 ACORDA THERAPEUTICS : Announces Long-Term Safety Data for CVT-301
04/05 ACORDA THERAPEUTICS : Implements Corporate Restructuring to Align Cost Structure..
03/31 ACORDA THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form ..
03/31 ACORDA THERAPEUTICS : U.S. District Court Issues Decision to Invalidate Four AMP..
More news
Sector news : Bio Therapeutic Drugs
12:35a AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/26$ACOR Will any analyst on tomorrow morning’s call ask @roncohenshair if he’s ..
1
04/26Upcoming #earnings conference calls, webcasts  
04/26Top Earnings Th 4/27 Pre: $AAL $AB $ABBV $ACOR $AEP $ALKS $ALLY $ALXN $AMT $A..
1
04/26Acorda Therapeutics Inc $ACOR Set to Announce Earnings on Thursday  
04/26Acorda Therapeutics Inc $ACOR Receives $29.45 Average PT from Analysts  
More tweets
Qtime:18
News from SeekingAlpha
04/26 Notable earnings before Thursday?s open
04/08 WEEK 15 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge
04/05 Acorda restructures, cuts headcount 20%
04/04 BIOTECH FORUM DAILY DIGEST : Acorda Therapeutics' Bleak Future, Invitae's Roll C..
04/03 Patent Rulings Knock Acorda And Forward
Advertisement
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Technical analysis trends ACORDA THERAPEUTI...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 28,4 $
Spread / Average Target 72%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
David Lawrence Chief Financial & Accounting Officer
Andrew R. Blight Chief Scientific Officer
Anthony O. Caggiano Vice President-Research & Development
Richard P. Batycky Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS IN..-14.89%772
AMGEN, INC.12.65%121 201
CELGENE CORPORATION8.44%97 650
GILEAD SCIENCES, INC.-6.27%87 742
REGENERON PHARMACEUTIC..1.32%39 496
ACTELION LTD26.67%30 320
More Results